FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul Sondel

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Mouse

Disorders

Procedures

Co-author Network

Publications

TOP 3
Kory L Alderson; Megan M Elsenheimer; Stephen D Gillies; Mitchell Luangrath; Fariba Navid; Alexander L Rakhmilevich; Paul M Sondel
Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
Tyler J Van De Voort; Richard K Yang; Mildred A R Felder; Paul M Sondel; Alexander L Rakhmilevich
Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.
Mark R Albertini; Jens Eickhoff; Brian Gadbaw; Jacek Gan; Stephen D Gillies; Jennifer Haldeman; Jacquelyn A Hank; KyungMann Kim; Jordan Kostlevy; Heidi Schalch; Paul M Sondel
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul Sondel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kory L Alderson; Megan M Elsenheimer; Stephen D Gillies; Mitchell Luangrath; Fariba Navid; Alexander L Rakhmilevich; Paul M Sondel
Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
Cancer immunology, immunotherapy : CII 2013;62(4):665-75.
2013: Tyler J Van De Voort; Richard K Yang; Mildred A R Felder; Paul M Sondel; Alexander L Rakhmilevich
Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2013;36(1):29-40.
2012: Mark R Albertini; Jens Eickhoff; Brian Gadbaw; Jacek Gan; Stephen D Gillies; Jennifer Haldeman; Jacquelyn A Hank; KyungMann Kim; Jordan Kostlevy; Heidi Schalch; Paul M Sondel
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
Cancer immunology, immunotherapy : CII 2012;61(12):2261-71.
2012: Alexander L Rakhmilevich; Tyler J Van De Voort; Nico van Rooijen; Richard K Yang; Mark J Baldeshwiler; Mildred A R Felder; Nicholas A Kalogriopoulos; David S Koslov; Paul M Sondel
Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.
Cancer immunology, immunotherapy : CII 2012;61(10):1683-97.
2012: Richard K Yang; Kory L Alderson; Jacek Gan; Stephen D Gillies; Jacquelyn A Hank; Nicholas A Kalogriopoulos; KyungMann Kim; Alexander L Rakhmilevich; Erik A Ranheim; Ralph A Reisfeld; Songwon Seo; Paul M Sondel
Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(5):2656-64.
2012: Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
T-cell-independent antitumor effects of CD40 ligation.
International reviews of immunology 2012;31(4):267-78.
2012: Tony A Koehn; Kimberly A McDowell; Lori L Trimble; Kory L Alderson; Amy K Erbe; Bartosz Grzywacz; Jacquelyn A Hank; Paul M Sondel
Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.
Frontiers in pharmacology 2012;3():91.
2011: Jennifer A A Gubbels; Jacquelyn A Hank; Sachi Horibata; Arvinder K Kapur; Manish S Patankar; Dhara Patel; Paul M Sondel; Ilia N Buhtoiarov; Brian Gadbaw; Stephen D Gillies; Joseph Connor
Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
Cancer immunology, immunotherapy : CII 2011;60(12):1789-800.
2011: Andrew J Russ; Christine M Seroogy; Paul M Sondel; Marulasiddappa Suresh; Lucy Wentworth; Kyle Xu; Alexander L Rakhmilevich; Clifford S Cho
Suppression of T-cell expansion by melanoma is exerted on resting cells.
Annals of surgical oncology 2011;18(13):3848-57.
2011: Judith G Villablanca; Susan Cohn; Barry Shulkin; Sarah A Buhrow; Brenda Joyce Kitchen; Hollie Jackson; Joel M Reid; Arlene Naranjo; Paul M Sondel; Gregory Yanik; Marguerite T Parisi; Renee M McGovern; Enno Stranzinger; Patrick McGrady; Matthew M Ames; Wendy B London; C Patrick Reynolds
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6858-66.
2011: Brenda L Soto; Eric M Yanke; Soesiawati R Darjatmoko; Stephen D Gillies; Jacquelyn A Hank; KyungMann Kim; Arthur S Polans; Alexander L Rakhmilevich; Ralph A Reisfeld; Songwon Seo; Paul M Sondel
Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.
International immunopharmacology 2011;11(11):1877-86.
2011: Beverly J Lange; Eric L Sievers; Richard K Yang; Todd A Alonzo; Jacek Gan; Robert B Gerbing; Jaquelyn A Hank; Paul M Sondel
Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.
Pediatric blood & cancer 2011;57(3):398-405.
2011: Brenda L Soto; Jacquelyn A Hank; Tyler J Van De Voort; Lalita Subramanian; Arthur S Polans; Alexander L Rakhmilevich; Richard K Yang; Songwong Seo; KyungMann Kim; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model.
Cancer immunology, immunotherapy : CII 2011;60(5):731-8.
2011: Ilia N Buhtoiarov; Zane C Neal; Jacek Gan; Tatiana N Buhtoiarova; Manish S Patankar; Jennifer A A Gubbels; Jacquelyn A Hank; Brett Yamane; Alexander L Rakhmilevich; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.
Journal of leukocyte biology 2011;89(4):625-38.
2011: Ilia N Buhtoiarov; Paul M Sondel; JON WIGGINTON; Tatiana N Buhtoiarova; Eric M Yanke; David A Mahvi; Alexander L Rakhmilevich
Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
Immunology 2011;132(2):226-39.
2011: Kory L Alderson; Paul M Sondel
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
Journal of biomedicine & biotechnology 2011;2011():379123.
2011: Erik E Johnson; Ilia N Buhtoiarov; Mark J Baldeshwiler; Mildred A R Felder; Nico van Rooijen; Paul M Sondel; Alexander L Rakhmilevich
Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2011;34(1):76-84.
2010: David C Delgado; Jacquelyn A Hank; Jill Kolesar; DF Lorentzen; Jacek Gan; Songwon Seo; KyungMann Kim; Suzanne Shusterman; Stephen D Gillies; Ralph A Reisfeld; Richard Yang; Brian Gadbaw; Kenneth B DeSantes; Wendy B London; Robert C Seeger; John M Maris; Paul M Sondel
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
Cancer research 2010;70(23):9554-61.
2010: Suzanne Shusterman; Wendy B London; Stephen D Gillies; Jacquelyn A Hank; Stephan D Voss; Robert C Seeger; Charles Patrick Reynolds; Jennifer Kimball; Mark R Albertini; Barrett Wagner; Jacek Gan; Jens Eickhoff; Kenneth B DeSantes; Susan Cohn; Toby Hecht; Brian Gadbaw; Ralph A Reisfeld; John M Maris; Paul M Sondel
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(33):4969-75.
2010: Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert C Seeger; Charles Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan Cohn; John M Maris; Paul M Sondel
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
The New England journal of medicine 2010;363(14):1324-34.
2010: Carl E Allen; Ricardo Flores; Ronald Rauch; Robert Dauser; Jeffrey C Murray; Diane Puccetti; David A Hsu; Paul M Sondel; Maxine Hetherington; Stan Goldman; Kenneth L McClain
Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside.
Pediatric blood & cancer 2010;54(3):416-23.
2009: Jacquelyn A Hank; Jacek Gan; Hyunji Ryu; Amy Ostendorf; Michael C Stauder; Adam Sternberg; Mark R Albertini; Kin-Ming Lo; Stephen D Gillies; Jens Eickhoff; Paul M Sondel
Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5923-30.
2009: Erik E Johnson; Brett H Yamane; Ilia N Buhtoiarov; Hillary D Lum; Alexander L Rakhmilevich; David M Mahvi; Stephen D Gillies; Paul M Sondel
Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(15):4875-84.
2009: Brett H Yamane; Jacquelyn A Hank; Mark R Albertini; Paul M Sondel
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
Expert opinion on investigational drugs 2009;18(7):991-1000.
2009: Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(11):6771-8.
2009: Christian M Capitini; Laurence J N Cooper; R Maarten Egeler; Rupert Handgretinger; Franco Locatelli; Paul M Sondel; CRYSTAL MACKALL
Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.
Journal of pediatric hematology/oncology 2009;31(4):227-44.
2009: Ilia N Buhtoiarov; Alexander L Rakhmilevich; Lewis L Lanier; Erik A Ranheim; Paul M Sondel
Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(4):1940-53.
2009: Andrew Gilman; M Fevzi Ozkaynak; Katherine K Matthay; Mark Krailo; Alice L Yu; Jacek Gan; Adam Sternberg; Jacquelyn A Hank; Robert C Seeger; Gregory H Reaman; Paul M Sondel
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):85-91.
2008: Erik E Johnson; Hillary D Lum; Alexander L Rakhmilevich; Brian E Schmidt; Meghan Furlong; Ilia N Buhtoiarov; Jacquelyn A Hank; Andrew Raubitschek; David Colcher; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Intratumoral immunocytokine treatment results in enhanced antitumor effects.
Cancer immunology, immunotherapy : CII 2008;57(12):1891-902.
2008: Holly J Meany; Nita L Seibel; Junfeng Sun; Jerry Z Finklestein; Judith Sato; John Kelleher; Paul M Sondel; Gregory Reaman
Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(7):679-83.
2008: Alexander L Rakhmilevich; Ilia N Buhtoiarov; Miroslav Malkovsky; Paul M Sondel
CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
Cancer immunology, immunotherapy : CII 2008;57(8):1151-60.
2008: Stephan A Grupp; Michael verneris; Paul M Sondel; Laurence J N Cooper
Immunotherapy for pediatric cancer.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(1 Suppl 1):33-43.
2007: Zane C Neal; Paul M Sondel; Mary Kay Bates; Stephen D Gillies; Hans Herweijer
Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory.
Cancer immunology, immunotherapy : CII 2007;56(11):1765-74.
2007: David M Mahvi; M B Henry; Mark R Albertini; S Weber; Kenneth Meredith; Heidi Schalch; Alexander L Rakhmilevich; Jacquelyn A Hank; Paul M Sondel
Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.
Cancer gene therapy 2007;14(8):717-23.
2007: naama peshes; Dalia Rosen; Paul M Sondel; Peter H Krammer; Gideon Berke
Up-regulation of Fas (CD95) expression in tumour cells in vivo.
Immunology 2007;120(4):502-11.
2007: Ilia N Buhtoiarov; Paul M Sondel; Jens Eickhoff; Alexander L Rakhmilevich
Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
Immunology 2007;120(3):412-23.
2007: Ryan D Cassaday; Paul M Sondel; David M King; Macklin Michael; Jacek Gan; Thomas F Warner; Cindy Zuleger; Alan J Bridges; Heidi G Schalch; Kyung Mann Kim; Jacquelyn A Hank; David M Mahvi; Mark R Albertini
A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):540-9.
2007: Erik Johnson; Shannon M Dean; Paul M Sondel
Antibody-based immunotherapy in high-risk neuroblastoma.
Expert reviews in molecular medicine 2007;9(34):1-21.
2006: Brian S Choi; Paul M Sondel; Jacquelyn A Hank; Heidi Schalch; Jacek Gan; David M King; Kari Kendra; David M Mahvi; Li-Yin Lee; KyungMann Kim; Mark R Albertini
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Cancer immunology, immunotherapy : CII 2006;55(7):761-74.
2006: Hillary D Lum; Ilia N Buhtoiarov; Brian E Schmidt; Gideon Berke; Donna M Paulnock; Paul M Sondel; Alexander L Rakhmilevich
Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.
Immunology 2006;118(2):261-70.
2006: Hillary D Lum; Ilia N Buhtoiarov; Brian E Schmidt; Gideon Berke; Donna M Paulnock; Paul M Sondel; Alexander L Rakhmilevich
In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Journal of leukocyte biology 2006;79(6):1181-92.
2006: Kaci L Osenga; Jacquelyn A Hank; Mark R Albertini; Jacek Gan; Adam G Sternberg; Jens Eickhoff; Robert C Seeger; Katherine K Matthay; Charles Patrick Reynolds; Clare Twist; Mark Krailo; Peter Charles Adamson; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1750-9.
2006: Ilia N Buhtoiarov; Hillary D Lum; Gideon Berke; Paul M Sondel; Alexander L Rakhmilevich
Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(1):309-18.
2005: Ilia N Buhtoiarov; Hillary D Lum; Gideon Berke; Donna M Paulnock; Paul M Sondel; Alexander L Rakhmilevich
CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(10):6013-22.
2005: Mark R Albertini; Jacquelyn A Hank; Paul M Sondel
Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.
Cancer chemotherapy and biological response modifiers 2005;22():789-97.
2004: Sharon M Weber; Chen Qi; Zane Neal; Paul M Sondel; David M Mahvi
IL-12 cDNA direct injection: antimetastatic effect from a single injection in a murine hepatic metastases model.
The Journal of surgical research 2004;122(2):210-7.
2004: David M King; Mark R Albertini; Heidi Schalch; Jacquelyn A Hank; Jacek Gan; Jean Surfus; David M Mahvi; Joan H Schiller; Thomas Warner; KyungMann Kim; Jens Eickhoff; Kari Kendra; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4463-73.
2004: Alexander L Rakhmilevich; Andrea T Hooper; Daniel J Hicklin; Paul M Sondel
Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
Molecular cancer therapeutics 2004;3(8):969-76.
2004: Zane C Neal; Jeannie C Yang; Alexander L Rakhmilevich; Ilia N Buhtoiarov; Hillary E Lum; Michael Imboden; Jacquelyn A Hank; Holger N Lode; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4839-47.
2004: Joseph P Connor; Mildred Felder; Jacquelyn A Hank; Josephine Harter; Jacek Gan; Stephen D Gillies; Paul M Sondel
Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(3):211-9.
2004: Zane C Neal; Michael Imboden; Alexander L Rakhmilevich; Kyung Mann Kim; Jacquelyn A Hank; Jean Surfus; John R Dixon; Holger N Lode; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.
Cancer immunology, immunotherapy : CII 2004;53(1):41-52.
2003: Michael Imboden; Fushun Shi; Thomas D Pugh; Aharon G Freud; Nathaniel J Thom; Jacquelyn A Hank; Zhengling Hao; S Tyler Staelin; Paul M Sondel; David M Mahvi
Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study.
Human gene therapy 2003;14(11):1037-48.
2003: Paul M Sondel; Ilia N Buhtoiarov; Kenneth DeSantes
Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease.
The Journal of clinical investigation 2003;112(1):25-7.
2003: Paul M Sondel; Jacquelyn A Hank; Jacek Gan; Zane C Neal; Mark R Albertini
Preclinical and clinical development of immunocytokines.
Current opinion in investigational drugs (London, England : 2000) 2003;4(6):696-700.
2003: Jacquelyn A Hank; Jean Surfus; Jacek Gan; Amy Ostendorf; Stephen D Gillies; Paul M Sondel
Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine.
Methods in molecular medicine 2003;85():123-31.
2002: David M Mahvi; F-S Shi; Ning-Sun Yang; S Weber; Jacquelyn A Hank; Mark R Albertini; J Schiller; Heidi Schalch; M Larson; L Pharo; Jacek Gan; D Heisey; Thomas Warner; Paul M Sondel
Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
Human gene therapy 2002;13(14):1711-21.
2002: Fushun Shi; Alexander L Rakhmilevich; Charles P Heise; Katsuhisa Oshikawa; Paul M Sondel; Ning-Sun Yang; David M Mahvi
Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model.
Molecular cancer therapeutics 2002;1(11):949-57.
2002: Jie-Hui Li; Dalia Rosen; Paul M Sondel; Gideon Berke
Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.
Immunology 2002;105(3):267-77.
2001: Patricia A Dinndorf; Mark Krailo; Wen Liu; S Frierdich; Paul M Sondel; Gregory Reaman
Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(6):511-6.
2001: Paul M Sondel; Jacquelyn A Hank
Antibody-directed, effector cell-mediated tumor destruction.
Hematology/oncology clinics of North America 2001;15(4):703-21.
2001: Alexander L Rakhmilevich; Michael Imboden; Zhengling Hao; Macklin Michael; T Roberts; K M Wright; Mark R Albertini; Ning-Sun Yang; Paul M Sondel
Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):952-61.
2001: N L Monson; T J Fenske; S Wei; AJ Okragly; JL de Jong; Mary Haak-Frendscho; John O'Shea; J Djeu; Paul M Sondel
A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line Tf-1beta2.
Journal of leukocyte biology 2001;69(3):419-25.
2001: Michael Imboden; K R Murphy; Alexander L Rakhmilevich; Zane C Neal; R Xiang; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Cancer research 2001;61(4):1500-7.
2001: M E Eastman; M Khorsand; Dennis G Maki; Eliot C Williams; K Kim; Paul M Sondel; Joan H Schiller; Mark R Albertini
Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2.
Cancer 2001;91(4):806-14.
2001: Katsuhisa Oshikawa; Alexander L Rakhmilevich; Fushun Shi; Paul M Sondel; N Yang; David M Mahvi
Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.
Human gene therapy 2001;12(2):149-60.
2001: J G Turner; Alexander L Rakhmilevich; Lyudmila Burdelya; Zane C Neal; Michael Imboden; Paul M Sondel; Hua Yu
Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(1):89-94.
2000: M Fevzi Ozkaynak; Paul M Sondel; Mark Krailo; J Gan; B Javorsky; R A Reisfeld; K K Matthay; G H Reaman; Robert C Seeger
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4077-85.
2000: Alexander L Rakhmilevich; K Janssen; Zhengling Hao; Paul M Sondel; Ning-Sun Yang
Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Cancer gene therapy 2000;7(6):826-38.
2000: K M Hotton; M Khorsand; Jacquelyn A Hank; Mark R Albertini; K M Kim; George Wilding; M S Salamat; M Larson; Paul M Sondel; Joan H Schiller
A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis.
Cancer 2000;88(8):1892-901.
2000: Eric L Sievers; Beverly J Lange; Paul M Sondel; M D Krailo; J Gan; TK Tjoa; Wen Liu; S A Feig
Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia.
The cancer journal from Scientific American 2000;6 Suppl 1():S39-44.
1999: Katsuhisa Oshikawa; Fushun Shi; Alexander L Rakhmilevich; Paul M Sondel; David M Mahvi; Ning-Sun Yang
Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(23):13351-6.
1999: S A Soergel; E Gregory MacEwen; David M Vail; D M Potter; Paul M Sondel; Stuart C Helfand
The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(5):443-53.
1999: Kari Kendra; Jacek Gan; M Ricci; Jean Surfus; A Shaker; Michael Super; J D Frost; Alexander L Rakhmilevich; Jacquelyn A Hank; Stephen D Gillies; Paul M Sondel
Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.
Cancer immunology, immunotherapy : CII 1999;48(5):219-29.
1999: J Gan; Kari Kendra; M Ricci; Jacquelyn A Hank; Stephen D Gillies; Paul M Sondel
Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.
Clinical and diagnostic laboratory immunology 1999;6(2):236-42.
1999: Jacquelyn A Hank; Jean Surfus; Jacek Gan; Mark R Albertini; Mary J Lindstrom; Joan H Schiller; K M Hotton; M Khorsand; Paul M Sondel
Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):281-9.
1999: Jacquelyn A Hank; Mark R Albertini; Paul M Sondel
Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease.
Cancer chemotherapy and biological response modifiers 1999;18():210-22.
1999: Paul M Sondel
Post-transplant immunotherapy designed to prevent cancer recurrence.
Pediatric transplantation 1999;3 Suppl 1():96-101.
1998: JL de Jong; NL Farner; Paul M Sondel
Distinctions in lymphocyte responses to IL-2 and IL-15 reflect differential ligand binding interactions with the IL-2Rbeta chain and suggest differential roles for the IL-2Ralpha and IL-15Ralpha subunits.
Cytokine 1998;10(12):920-30.
1998: CM Nicolet; J M Surfus; Jacquelyn A Hank; Paul M Sondel
Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy.
Cancer immunology, immunotherapy : CII 1998;46(6):327-37.
1998: JL de Jong; NL Farner; B R Javorsky; Mary J Lindstrom; Jacquelyn A Hank; Paul M Sondel
Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1287-96.
1998: Eric L Sievers; Beverly J Lange; Paul M Sondel; Mark Krailo; J Gan; Wen Liu; S A Feig
Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):914-9.
1997: Paul M Sondel; Jacquelyn A Hank
Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
The cancer journal from Scientific American 1997;3 Suppl 1():S121-7.
1997: Mark R Albertini; Jacquelyn A Hank; Joan H Schiller; M Khorsand; A A Borchert; Jacek Gan; R Bechhofer; B Storer; Ralph A Reisfeld; Paul M Sondel
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(8):1277-88.
1997: J D Frost; Jacquelyn A Hank; Gregory H Reaman; S Frierdich; Robert C Seeger; Jacek Gan; P M Anderson; Lawrence J Ettinger; Mitchell S Cairo; BR Blazar; Mark Krailo; K K Matthay; Ralph A Reisfeld; Paul M Sondel
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
Cancer 1997;80(2):317-33.
1997: NL Farner; J Gan; JL de Jong; T P Leary; T S Fenske; P Buckley; S Dunlap; Paul M Sondel
Alteration of the CD34+ Tf-1 beta cell line profile in response to long-term exposure to IL-15.
Cytokine 1997;9(5):316-27.
1997: R Szydlo; John M Goldman; John P Klein; Robert Peter Gale; R C Ash; F H Bach; Benjamin A Bradley; James T Casper; Neal Flomenberg; James L Gajewski; Eliane Gluckman; PJ Henslee-Downey; Jill M Hows; Niels Jacobsen; Hans-Jochem Kolb; B Lowenberg; T Masaoka; Philip Rowlings; Paul M Sondel; D W van Bekkum; Jon van Rood; MR Vowels; Mei-Jie Zhang; Mary M Horowitz
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1767-77.
1997: David M Mahvi; Paul M Sondel; Ning-Sun Yang; Mark R Albertini; Joan H Schiller; Jacquelyn A Hank; J Heiner; Jacek Gan; William Foster Swain; R Logrono
Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma.
Human gene therapy 1997;8(7):875-91.
1997: CM Nicolet; D H Siegel; Jean Surfus; Paul M Sondel
TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1997;18(6):356-66.
1996: Jacquelyn A Hank; Jean Surfus; Jacek Gan; P Jaeger; S D Gillies; R A Reisfeld; Paul M Sondel
Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(12):1951-9.
1996: David M Mahvi; JK Burkholder; J Turner; J Culp; James S Malter; Paul M Sondel; Ning-Sun Yang
Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine.
Human gene therapy 1996;7(13):1535-43.
1996: Mark R Albertini; Jacek Gan; P Jaeger; Jacquelyn A Hank; B Storer; K Schell; T Rivest; Jean Surfus; R A Reisfeld; Joan H Schiller; Paul M Sondel
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(4):278-95.
1996: Alexander L Rakhmilevich; J Turner; M J Ford; D McCabe; W H Sun; Paul M Sondel; K Grota; Ning-Sun Yang
Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(13):6291-6.
1996: Jean Surfus; Jacquelyn A Hank; Egbert Oosterwijk; Sydney Welt; Mary J Lindstrom; Mark R Albertini; Joan H Schiller; Paul M Sondel
Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):184-91.
1996: JL de Jong; N L Farner; M B Widmer; Judith Goldstein Giri; Paul M Sondel
Interaction of IL-15 with the shared IL-2 receptor beta and gamma c subunits. The IL-15/beta/gamma c receptor-ligand complex is less stable than the IL-2/beta/gamma c receptor-ligand complex.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(4):1339-48.
1996: Joan H Schiller; Jacquelyn A Hank; M Khorsand; B Storer; A Borchert; K Huseby-Moore; D Burns; O Wesly; Mark R Albertini; George Wilding; Paul M Sondel
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(2):319-30.
1996: Stuart C Helfand; Jacquelyn A Hank; Jacek Gan; Paul M Sondel
Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Cellular immunology 1996;167(1):99-107.
1995: N L Farner; S D Voss; T P Leary; J Gan; J Hakimi; G Evans; G Ju; Paul M Sondel
Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1.
Blood 1995;86(12):4568-78.
1995: N L Farner; S D Voss; Paul M Sondel
X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis.
Clinical and diagnostic laboratory immunology 1995;2(5):518-23.
1995: C M Nicolet; JK Burkholder; Jacek Gan; J Culp; S V Kashmiri; J Schlom; Ning-Sun Yang; Paul M Sondel
Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery.
Cancer gene therapy 1995;2(3):161-70.
1995: Stuart C Helfand; Jaime F Modiano; Peter F Moore; S A Soergel; PS MacWilliams; R D Dubielzig; Jacquelyn A Hank; E W Gelfand; Paul M Sondel
Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma.
Blood 1995;86(2):636-45.
1995: M Bauer; Gregory H Reaman; J A Hank; Mitchell S Cairo; P Anderson; B R Blazar; S Frierdich; Paul M Sondel
A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study.
Cancer 1995;75(12):2959-65.
1995: David M Mahvi; J A Madsen; P L Witt; Paul M Sondel
Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.
Cancer immunology, immunotherapy : CII 1995;40(5):311-4.
1994: Stuart C Helfand; S A Soergel; R L Donner; Jacek Gan; Jacquelyn A Hank; Mary J Lindstrom; Paul M Sondel
Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):188-97.
1994: Stuart C Helfand; S A Soergel; PS MacWilliams; Jacquelyn A Hank; Paul M Sondel
Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.
Cancer immunology, immunotherapy : CII 1994;39(2):84-92.
1994: Nita L Seibel; Patricia A Dinndorf; M Bauer; Paul M Sondel; G D Hammond; Gregory H Reaman
Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: a Children's Cancer Group study.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(2):125-31.
1994: Paul M Sondel; S D Voss; R Hong
Addendum to SCID, interleukin-2, and the interleukin-2 receptor review.
Blood 1994;84(2):667-8.
1994: I Kaur; J de Jong; K Schell; Jacquelyn A Hank; Paul Fisch; Paul M Sondel
Human peripheral gamma delta T cells are stimulated by Daudi Burkitt's lymphoma and not by any other Burkitt's lymphoma tested.
Cellular immunology 1994;156(1):54-61.
1994: K R Oettel; O H Wesly; Mark R Albertini; Jacquelyn A Hank; O Iliopolis; Jeffrey A Sosman; K Voelkerding; S Q Wu; Steven S Clark; Paul M Sondel
Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient.
Blood 1994;83(11):3390-402.
1994: S D Voss; R Hong; Paul M Sondel
Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way.
Blood 1994;83(3):626-35.
1994: J D Frost; Paul M Sondel
Immunotherapy for infection and malignancy in children with cancer.
Advances in pediatrics 1994;41():385-413.
1994: Stuart C Helfand; S A Soergel; Jaime F Modiano; Jacquelyn A Hank; Paul M Sondel
Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Cancer biotherapy 1994;9(3):237-44.
1993: Jacquelyn A Hank; Mark R Albertini; J Schiller; Paul M Sondel
Activation of multiple effector mechanisms to enhance tumor immunotherapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(4):329-35.
1993: David M Mahvi; Stephen W Carper; F K Storm; S R Teal; Paul M Sondel
Overexpression of 27-kDa heat-shock protein in MCF-7 breast cancer cells: effects on lymphocyte-mediated killing by natural killer and gamma delta T cells.
Cancer immunology, immunotherapy : CII 1993;37(3):181-6.
1993: Paul M Sondel
Biologic and immunologic approaches to comprehensive therapy for pediatric malignant conditions. Laboratory-clinical interaction.
Cancer 1993;71(10 Suppl):3429-34.
1993: Michael P Link; J Stevens; S H Friend; Mark Israel; Alfred G Knudson; Paul M Sondel
Laboratory-clinical interface.
Cancer 1993;71(10 Suppl):3219-21.
1993: Mark R Albertini; S P Howard; Paul Fisch; Mary J Lindstrom; Jacquelyn A Hank; Michael N Gould; Paul M Sondel
Modulation of target-cell culture conditions alters susceptibility to lymphocyte-mediated lysis.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(4):243-51.
1993: Jeffrey A Sosman; Paul M Sondel
The graft-vs.-leukemia effect. Implications for post-marrow transplant antileukemia treatment.
The American journal of pediatric hematology/oncology 1993;15(2):185-95.
1993: S D Voss; T P Leary; Paul M Sondel; R J Robb
Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(6):2428-32.
1993: I Kaur; S D Voss; R S Gupta; K Schell; Paul Fisch; Paul M Sondel
Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(5):2046-55.
1993: O Ringdén; Mary M Horowitz; Paul M Sondel; Robert Peter Gale; J C Biggs; Richard E Champlin; H J Deeg; K Dicke; T Masaoka; R L Powles
Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?
Blood 1993;81(4):1094-101.
1993: Paul M Sondel
Introduction: advances in pediatric bone marrow transplantation.
The American journal of pediatric hematology/oncology 1993;15(1):1-2.
1993: T Yabe; C McSherry; F H Bach; Paul Fisch; R P Schall; Paul M Sondel; J P Houchins
A multigene family on human chromosome 12 encodes natural killer-cell lectins.
Immunogenetics 1993;37(6):455-60.
1993: C Gambacorti-Passerini; Jacquelyn A Hank; Mark R Albertini; A A Borchert; K H Moore; Joan H Schiller; R Bechhofer; Ernest C Borden; B Storer; Paul M Sondel
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(1):43-8.
1992: M Roper; M A Smith; Paul M Sondel; A Gillespie; G H Reaman; G D Hammond; D Levitt; Angelo Rosolen; Oscar R Colamonici; L M Neckers
A phase I study of interleukin-2 in children with cancer.
The American journal of pediatric hematology/oncology 1992;14(4):305-11.
1992: Bruce S Klein; Paul M Sondel; J M Jones
WI-1, a novel 120-kilodalton surface protein on Blastomyces dermatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis.
Infection and immunity 1992;60(10):4291-300.
1992: S D Voss; Paul M Sondel; R J Robb
Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R.
The Journal of experimental medicine 1992;176(2):531-41.
1992: Paul Fisch; K Oettel; N Fudim; Jean Surfus; Miroslav Malkovsky; Paul M Sondel
MHC-unrestricted cytotoxic and proliferative responses of two distinct human gamma/delta T cell subsets to Daudi cells.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(8):2315-23.
1992: M P Bogner; S D Voss; R Bechhofer; Jacquelyn A Hank; M Roper; D Poplack; D Hammond; Paul M Sondel
Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(2):111-8.
1992: Mark R Albertini; D F Gibson; S P Robinson; S P Howard; K J Tans; Mary J Lindstrom; R R Robinson; D C Tormey; V C Jordan; Paul M Sondel
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(1):30-9.
1992: Mark R Albertini; Jacquelyn A Hank; Paul M Sondel
Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2.
Biotherapy (Dordrecht, Netherlands) 1992;4(3):189-98.
1992: Paul M Sondel; H Kawai; O H Wesly
Harnessing graft versus leukemia: implications for IL-2 treatment.
Bone marrow transplantation 1992;10 Suppl 1():13-5.
1991: C Gambacorti-Passerini; Jacquelyn A Hank; A Borchert; K Moore; V Malkovska; Paul M Sondel
In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients.
Tumori 1991;77(5):420-2.
1991: Joan H Schiller; Mary J Lindstrom; P L Witt; J A Hank; David M Mahvi; R J Wagner; Paul M Sondel; Ernest C Borden
Immunological effects of levamisole in vitro.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(5):297-306.
1991: G Weil-Hillman; K Schell; D M Segal; Jacquelyn A Hank; Jeffrey A Sosman; Paul M Sondel
Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(4):267-77.
1991: Paul M Sondel
Interleukin-2: prospects for lymphocyte-mediated destruction of pediatric malignancies.
The Journal of pediatrics 1991;118(3):S14-6.
1991: Jeffrey A Sosman; Paul M Sondel
The graft versus leukemia effect: possible mechanisms and clinical significance to the biologic therapy of leukemia.
Bone marrow transplantation 1991;7 Suppl 1():33-7.
1991: A Cannon; Jacquelyn A Hank; Paul M Sondel
BLT-esterase activity following in vitro and in vivo activation of human lymphocytes with interleukin-2. In vivo IL-2 induces BLT-esterase.
Biotherapy (Dordrecht, Netherlands) 1991;3(3):253-60.
1991: E Sturm; Eric Braakman; Paul Fisch; Paul M Sondel; Reinder L H Bolhuis
Daudi cell specificity correlates with the use of a V gamma 9-V delta 2 encoded TCR gamma delta.
Current topics in microbiology and immunology 1991;173():183-8.
1991: Paul Fisch; S Kovats; N Fundim; E Sturm; Eric Braakman; R DeMars; Reinder L H Bolhuis; Paul M Sondel; Miroslav Malkovsky
Function and specificity of human V gamma 9/V delta 2 T lymphocytes.
Current topics in microbiology and immunology 1991;173():179-82.
1991: Mark R Albertini; J A Nicklas; B F Chastenay; T C Hunter; R J Albertini; Steven S Clark; Jacquelyn A Hank; Paul M Sondel
Analysis of T cell receptor beta and gamma genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patients.
Cancer immunology, immunotherapy : CII 1991;32(5):325-30.
1991: R R Brown; Y Ozaki; S P Datta; Ernest C Borden; Paul M Sondel; D G Malone
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
Advances in experimental medicine and biology 1991;294():425-35.
1990: Mark R Albertini; Jeffrey A Sosman; Jacquelyn A Hank; K H Moore; A Borchert; K Schell; P C Kohler; R Bechhofer; B Storer; Paul M Sondel
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.
Cancer 1990;66(12):2457-64.
1990: C Gambacorti-Passerini; Paul M Sondel
Problems, controversies, and perspectives on the clinical use of interleukin-2.
Current opinion in oncology 1990;2(6):1139-45.
1990: E Sturm; Eric Braakman; Paul Fisch; R J Vreugdenhil; Paul M Sondel; Reinder L H Bolhuis
Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(10):3202-8.
1990: Mark R Albertini; K R Oettel; G Weil-Hillman; Mary J Lindstrom; K Schell; Jacquelyn A Hank; Paul M Sondel
Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
Journal of biological response modifiers 1990;9(5):456-62.
1990: S D Voss; R J Robb; G Weil-Hillman; Jacquelyn A Hank; K Sugamura; M Tsudo; Paul M Sondel
Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.
The Journal of experimental medicine 1990;172(4):1101-14.
1990: Jacquelyn A Hank; R R Robinson; Jean Surfus; B M Mueller; R A Reisfeld; Nai-Kong V Cheung; Paul M Sondel
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Cancer research 1990;50(17):5234-9.
1990: Reinder L H Bolhuis; E Sturm; Paul Fisch; Paul M Sondel; Eric Braakman
Human gamma delta T lymphocyte subsets: activation by superantigens?
Research in immunology 1990;141(7):658-63.
1990: V Lam; R DeMars; B P Chen; Jacquelyn A Hank; S Kovats; Paul Fisch; Paul M Sondel
Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DP.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(1):36-45.
1990: Jeffrey A Sosman; K R Oettel; S D Smith; Jacquelyn A Hank; Paul Fisch; Paul M Sondel
Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.
Blood 1990;75(10):2005-16.
1990: Paul Fisch; Miroslav Malkovsky; Eric Braakman; E Sturm; Reinder L H Bolhuis; A Prieve; Jeffrey A Sosman; V A Lam; Paul M Sondel
Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis.
The Journal of experimental medicine 1990;171(5):1567-79.
1990: G Weil-Hillman; S D Voss; Paul Fisch; K Schell; Jacquelyn A Hank; Jeffrey A Sosman; K Sugamura; Paul M Sondel
Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
Cancer research 1990;50(9):2683-91.
1990: Julie B Sedgwick; W E Frick; Paul M Sondel; J A Hank; Ernest C Borden; William W Busse
The appearance of hypodense eosinophils during interleukin-2 treatment.
The Journal of allergy and clinical immunology 1990;85(3):557-66.
1990: Ernest C Borden; Paul M Sondel
Lymphokines and cytokines as cancer treatment. Immunotherapy realized.
Cancer 1990;65(3 Suppl):800-14.
1990: Jeffrey A Sosman; J A Hank; Paul M Sondel
In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies.
Seminars in oncology 1990;17(1 Suppl 1):22-30; discussion 38-41.
1990: Mary M Horowitz; Robert Peter Gale; Paul M Sondel; John M Goldman; J Kersey; Hans-Jochem Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood 1990;75(3):555-62.
1990: Jacquelyn A Hank; Jeffrey A Sosman; P C Kohler; R Bechhofer; B Storer; Paul M Sondel
Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.
Journal of biological response modifiers 1990;9(1):5-14.
1990: Jacquelyn A Hank; G Weil-Hillman; Jean Surfus; Jeffrey A Sosman; Paul M Sondel
Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.
Cancer immunology, immunotherapy : CII 1990;31(1):53-9.
1990: V Malkovska; Paul M Sondel
Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
Journal of the National Cancer Institute. Monographs 1990;(10):69-72.
1990: A J Bridges; D Norback; Paul Fisch; D England; Paul M Sondel
T helper-cell leukemia/lymphoma: presentation as an acute immune-mediated illness.
Journal of clinical immunology 1990;10(1):61-70.
1990: I B Rosenzweig; D A Wiebe; J A Hank; J J Albers; J L Adolphson; Ernest C Borden; E S Shrago; Paul M Sondel
Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein.
Biotherapy (Dordrecht, Netherlands) 1990;2(3):193-8.
1989: B P Chen; V Lam; E E Kraus; R DeMars; Paul M Sondel
Restriction of Epstein-Barr virus-specific cytotoxic T cells by HLA-A, -B, and -C molecules.
Human immunology 1989;26(2):137-47.
1989: R R Brown; C M Lee; P C Kohler; Jacquelyn A Hank; Barry E Storer; Paul M Sondel
Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.
Cancer research 1989;49(17):4941-4.
1989: Jeffrey A Sosman; K R Oettel; Jacquelyn A Hank; Paul Fisch; Paul M Sondel
Specific recognition of human leukemic cells by allogeneic T cell lines.
Transplantation 1989;48(3):486-95.
1989: Paul Fisch; G Weil-Hillman; M Uppenkamp; Jacquelyn A Hank; B P Chen; Jeffrey A Sosman; A Bridges; Oscar R Colamonici; Paul M Sondel
Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia.
Blood 1989;74(1):343-53.
1989: G Weil-Hillman; Paul Fisch; A F Prieve; Jeffrey A Sosman; Jacquelyn A Hank; Paul M Sondel
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Cancer research 1989;49(13):3680-8.
1989: V Malkovska; Paul M Sondel; M Malkovský
Tumour immunotherapy.
Current opinion in immunology 1989;1(5):883-90.
1989: Paul M Sondel; Jeffrey A Sosman; J A Hank; P C Kohler; B Storer
Tumor-infiltrating lymphocytes and interleukin-2 in melanomas.
The New England journal of medicine 1989;320(21):1418-9.
1989: B P Chen; Jacquelyn A Hank; E E Kraus; Paul M Sondel
Selective lysis of target cells by interleukin-2-expanded peripheral blood mononuclear leukocyte clones.
Cellular immunology 1989;118(2):458-69.
1989: P C Kohler; Jacquelyn A Hank; K H Moore; B Storer; R Bechhofer; R Hong; Paul M Sondel
Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
Cancer investigation 1989;7(3):213-23.
1989: S D Voss; Jacquelyn A Hank; C A Nobis; Paul Fisch; Jeffrey A Sosman; Paul M Sondel
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.
Cancer immunology, immunotherapy : CII 1989;29(4):261-9.
1989: P C Kohler; Paul M Sondel
The role of interleukin-2 in cancer therapy.
Cancer surveys 1989;8(4):861-73.
1989: Paul M Sondel; Jacquelyn A Hank
Prospects for clinical cancer treatment using interleukin-2.
Cancer investigation 1989;7(5):437-42.
1989: S D Voss; G Weil-Hillman; Jacquelyn A Hank; Jeffrey A Sosman; Paul M Sondel
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.
Bulletin of the New York Academy of Medicine 1989;65(1):93-110.
1989: Paul M Sondel; Jacquelyn A Hank; P C Kohler; Jeffrey A Sosman; G Weil-Hillman; Paul Fisch
The cellular immunotherapy of cancer: current and potential uses of interleukin-2.
Critical reviews in oncology/hematology 1989;9(2):125-47.
1989: Paul M Sondel; Jacquelyn A Hank; P C Kohler; B P Chen; Jeffrey A Sosman
"Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
Progress in clinical and biological research 1989;288():151-60.
1989: J M Carlin; Ernest C Borden; Paul M Sondel; Gerald Byrne
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes.
Journal of leukocyte biology 1989;45(1):29-34.
1988: Jeffrey A Sosman; P C Kohler; Jacquelyn A Hank; K H Moore; R Bechhofer; B Storer; Paul M Sondel
Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.
Journal of the National Cancer Institute 1988;80(18):1451-61.
1988: M Malkovský; Paul M Sondel; W Strober; A G Dalgleish
The interleukins in acquired disease.
Clinical and experimental immunology 1988;74(2):151-61.
1988: G Weil-Hillman; Jacquelyn A Hank; N S Rosenthal; Paul M Sondel
Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.
Journal of biological response modifiers 1988;7(5):424-37.
1988: B P Chen; R DeMars; Jacquelyn A Hank; Paul M Sondel
CD4+ proliferative T-cell clones reactive to autologous Epstein-Barr virus-transformed B cells (EBV-LCL) can be restricted by HLA class I molecules.
Cellular immunology 1988;115(2):363-72.
1988: Paul M Sondel; P C Kohler; Jacquelyn A Hank; K H Moore; N S Rosenthal; Jeffrey A Sosman; R Bechhofer; B Storer
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
Cancer research 1988;48(9):2561-7.
1988: N S Rosenthal; Jacquelyn A Hank; P C Kohler; D Z Minkoff; K H Moore; R Bechhofer; R Hong; B Storer; Paul M Sondel
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
Journal of biological response modifiers 1988;7(2):123-39.
1988: Jacquelyn A Hank; P C Kohler; G Weil-Hillman; N Rosenthal; K H Moore; B Storer; D Minkoff; J Bradshaw; R Bechhofer; Paul M Sondel
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.
Cancer research 1988;48(7):1965-71.
1988: Jeffrey A Sosman; P C Kohler; Jacquelyn A Hank; K H Moore; R Bechhofer; B Storer; Paul M Sondel
Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
Journal of the National Cancer Institute 1988;80(1):60-3.
1988: P C Kohler; Jacquelyn A Hank; D Z Minkoff; Paul M Sondel
Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions.
Cancer immunology, immunotherapy : CII 1988;26(1):74-82.
1988: P J Orchard; H L Moffet; G R Hafez; Paul M Sondel
Pseudomonas sepsis simulating acute promyelocytic leukemia.
The Pediatric infectious disease journal 1988;7(1):66-8.
1988: William J Burlingham; A Grailer; Paul M Sondel; Hans W Sollinger
Improved renal allograft survival following donor-specific transfusions. III. Kinetics of mixed lymphocyte culture responses before and after transplantation.
Transplantation 1988;45(1):127-32.
1987: M Malkovský; Paul M Sondel
Interleukin 2 and its receptor: structure, function and therapeutic potential.
Blood reviews 1987;1(4):254-66.
1987: B P Chen; Miroslav Malkovsky; Jacquelyn A Hank; Paul M Sondel
Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb.
Cellular immunology 1987;110(2):282-93.
1987: J M Carlin; Ernest C Borden; Paul M Sondel; Gerald Byrne
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(7):2414-8.
1987: R C Moen; S D Horowitz; Paul M Sondel; W R Borcherding; ME Trigg; R Billing; R Hong
Immunologic reconstitution after haploidentical bone marrow transplantation for immune deficiency disorders: treatment of bone marrow cells with monoclonal antibody CT-2 and complement.
Blood 1987;70(3):664-9.
1987: Paul M Sondel; J A Hank; P C Kohler
Status and potential of interleukin-2 for the treatment of neoplastic disease.
Oncology (Williston Park, N.Y.) 1987;1(6):41-9.
1987: J L Weese; S E Emoto; Paul M Sondel
Reduced incidence of hepatic metastases by perioperative treatment with recombinant human interleukin-2.
Diseases of the colon and rectum 1987;30(7):503-7.
1987: R B Mandell; J A Hank; B P Chen; H I Robins; Paul M Sondel
Differential antigen presentation by heat-treated peripheral blood mononuclear cells and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL): heated EBV-LCL present alloantigen and soluble antigen but are deficient in the stimulation of autologous EBV-LCL primed T cells.
Human immunology 1987;19(3):163-77.
1987: A C Ochoa; G Gromo; B J Alter; Paul M Sondel; F H Bach
Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(8):2728-33.
1987: R Hong; S Horowitz; R Moen; ME Trigg; Paul M Sondel; R Billing; W Borcherding; J P Johnson; M Kanoff; W B Bias
Thymus and B cell reconstitution in severe combined immunodeficiency after transplantation of monoclonal antibody depleted parental mismatched bone marrow.
Bone marrow transplantation 1987;1(4):405-9.
1987: William J Burlingham; A Grailer; E M Sparks-Mackety; Paul M Sondel; Hans W Sollinger
Kinetics of antidonor mixed lymphocyte culture responses in donor specific transfusions plus azathioprine-treated patients.
Transplantation proceedings 1987;19(1 Pt 3):2255-7.
1987: B P Chen; R DeMars; Paul M Sondel
Presentation of soluble antigen to human T cells by products of multiple HLA-linked loci: analysis of antigen presentation by a panel of cloned, autologous, HLA-mutant Epstein-Barr virus-transformed lymphoblastoid cell lines.
Human immunology 1987;18(1):75-91.
1987: Paul M Sondel; Jacquelyn A Hank; N Rosenthal; K H Moore; R Hong; B Storer; P C Kohler
Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).
Progress in clinical and biological research 1987;244():173-84.
1987: P C Kohler; Jacquelyn A Hank; K H Moore; B Storer; R Bechhofer; Paul M Sondel
Phase 1 clinical evaluation of recombinant interleukin-2.
Progress in clinical and biological research 1987;244():161-72.
1987: P J Orchard; J D Dickerman; C H Mathews; S Frierdich; R Hong; ME Trigg; N T Shahidi; Jonathan Lester Finlay; Paul M Sondel
Haploidentical bone marrow transplantation for osteopetrosis.
The American journal of pediatric hematology/oncology 1987;9(4):335-40.
1987: Paul M Sondel; Jacquelyn A Hank; B P Chen; R Mandell; Jeffrey A Sosman; P C Kohler
Overview: cellular immunotherapy of cancer.
Progress in clinical and biological research 1987;244():3-14.
1987: A C Ochoa; R J Migliori; B J Alter; Paul M Sondel; R L Simmons; F H Bach
Long-term culture of LAK cells: expansion and activation signals.
Progress in clinical and biological research 1987;244():289-99.
1987: William J Burlingham; A Grailer; E M Sparks-Mackety; Paul M Sondel; H W Sollinger
Improved renal allograft survival following donor-specific transfusions. II. In vitro correlates of early (DST-type) rejection episodes.
Transplantation 1987;43(1):41-6.
1986: L S Cooperman; Marvin Garovoy; Paul M Sondel
Association of the HLA-DR2/DR4 phenotype with skin test responses to bovine dermal collagen: a potential interaction of two MHC alleles in regulating an immune response.
Human immunology 1986;17(4):471-9.
1986: P C Kohler; C Erickson; Jonathan Lester Finlay; M E Trigg; B Edwards; R Hong; Jacquelyn A Hank; R Billing; M Bozdech; Paul M Sondel
In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Cancer research 1986;46(10):5413-8.
1986: B P Chen; Paul M Sondel
Cytotoxicity of autologous Epstein-Barr virus-transformed cells mediated by interleukin-2 dependent, long-term T cell cultures is augmented by beta, but not alpha, recombinant interferon.
Journal of biological response modifiers 1986;5(4):351-61.
1986: Paul M Sondel; Jacquelyn A Hank; P C Kohler; B P Chen; D Z Minkoff; J A Molenda
Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(2):502-11.
1986: Pamela Reitnauer; R DeMars; Paul M Sondel
The proliferative immune response to autologous Epstein-Barr virus transformed lymphoblastoid cells. II. Studies with HLA class II loss variants demonstrate a role for gene products other than DR and DQ.
Human immunology 1986;16(3):276-88.
1986: Paul M Sondel; Jacquelyn A Hank; ME Trigg; P C Kohler; Jonathan Lester Finlay; J Blank; L Meisner; W Borcherding; R Hong; R Steeves
Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: autologous marrow recovery with specific immune sensitization to donor antigens.
Experimental hematology 1986;14(4):278-86.
1986: J Skinner; Jonathan Lester Finlay; Paul M Sondel; M E Trigg
Infectious complications in pediatric patients undergoing transplantation with T lymphocyte-depleted bone marrow.
Pediatric infectious disease 1986;5(3):319-24.
1986: Pamela Reitnauer; L R Brown; J A Hank; Paul M Sondel
Presentation of Candida albicans and purified protein derivative soluble antigens by Epstein-Barr virus-transformed human lymphoblastoid B-cell lines.
Cellular immunology 1986;99(1):196-208.
1986: J Lifson; A Raubitschek; Claudia Benike; K Koths; A Ammann; Paul M Sondel; Edgar G Engleman
Purified interleukin-2 induces proliferation of fresh human lymphocytes in the absence of exogenous stimuli.
Journal of biological response modifiers 1986;5(1):61-72.
1986: ME Trigg; A Peterson; C Erickson; M Bozdech; R Billing; Paul M Sondel; Jonathan Lester Finlay; J Surfus; M Stuiber; R Hong
Depletion of T cells from bone marrow for allogeneic transplantation: method for treatment of bone marrow in bulk.
Experimental hematology 1986;14(1):21-6.
1986: Jonathan Lester Finlay; D J Ganick; N Shahidi; W Borcherding; R Hong; Paul M Sondel
T-lymphoblasts with erythropoietic helper function in acute T-cell leukemia.
Pediatric hematology and oncology 1986;3(3):273-82.
1985: ME Trigg; Paul M Sondel; R Billing; Jonathan Lester Finlay; A Peterson; R Hong; S Frierdich; N Shahidi
Mismatched bone marrow transplantation in children with hematologic malignancy using T lymphocyte depleted bone marrow.
Journal of biological response modifiers 1985;4(6):602-12.
1985: M J Bozdech; Paul M Sondel; ME Trigg; W Longo; P C Kohler; B Flynn; R Billing; S A Anderson; Jacquelyn A Hank; R Hong
Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection.
Experimental hematology 1985;13(11):1201-10.
1985: Paul M Sondel; Jacquelyn A Hank; J Molenda; J Blank; W Borcherding; W Longo; ME Trigg; R Hong; M J Bozdech
Relapse of host leukemic lymphoblasts following engraftment by an HLA-mismatched marrow transplant: mechanisms of escape from the "graft versus leukemia" effect.
Experimental hematology 1985;13(8):782-90.
1985: Bradford S. Schwartz; Pamela Reitnauer; J A Hank; Paul M Sondel
A human T cell clone that mediates the monocyte procoagulant response to specific sensitizing antigen.
The Journal of clinical investigation 1985;76(3):1279-82.
1985: Pamela Reitnauer; R DeMars; Paul M Sondel
The proliferative immune response to autologous Epstein-Barr virus-transformed lymphoblastoid cells. I. Studies with HLA haplotype loss variants demonstrate a role for MHC-linked genes.
Human immunology 1985;13(3):177-91.
1985: M E Trigg; Jonathan Lester Finlay; Paul M Sondel
Prophylactic acyclovir in patients receiving bone marrow transplants.
The New England journal of medicine 1985;312(26):1708-9.
1985: B P Chen; Paul M Sondel
Recombinant DNA-derived interferons-alpha and -beta modulate the alloactivated proliferative response of bulk and cloned human lymphocytes.
Journal of biological response modifiers 1985;4(3):287-97.
1985: P Aebersold; B Chen; Paul M Sondel
Effects of interferon and radiation dose on the suppressive activity of human lymphocytes primed with allogeneic cells in mixed lymphocyte cultures.
Journal of biological response modifiers 1985;4(3):251-7.
1985: ME Trigg; R Billing; Paul M Sondel; R Exten; R Hong; M J Bozdech; S D Horowitz; Jonathan Lester Finlay; R Moen; W Longo
Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.
Cancer treatment reports 1985;69(4):377-86.
1985: P C Kohler; Jacquelyn A Hank; R Exten; D Z Minkoff; D G Wilson; Paul M Sondel
Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial.
Cancer 1985;55(3):552-60.
1985: J L Blank; J A Hank; J Molenda; W Borcherding; L Meisner; Paul M Sondel
HLA typing and karyotyping of limited numbers of lymphocytes is facilitated by in vitro expansion with TCGF.
Diagnostic immunology 1985;3(1):29-32.
1985: W J Burlingham; E M Sparks; Paul M Sondel; N R Glass; F O Belzer; H W Sollinger
Improved renal allograft survival following donor-specific transfusions. I. Induction of antibodies that inhibit primary antidonor MLC response.
Transplantation 1985;39(1):12-7.
1984: H Ian Robins; W H Dennis; P A Martin; Paul M Sondel; M B Yatvin; R A Steeves
Potentiation of differential hyperthermic sensitivity of AKR leukemia and normal bone marrow cells by lidocaine or thiopental.
Cancer 1984;54(12):2831-5.
1984: W J Burlingham; E M Sparks; G A Heatley; Paul M Sondel; N R Glass; F O Belzer; H W Sollinger
Mechanism of action of donor-specific transfusion: inhibition of mixed lymphocyte culture response by patient plasma.
Transplantation proceedings 1984;16(6):1451-3.
1984: R DeMars; C C Chang; S Shaw; Pamela Reitnauer; Paul M Sondel
Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens.
Human immunology 1984;11(2):77-97.
1984: H Ian Robins; W H Dennis; R A Steeves; Paul M Sondel
A proposal for the addition of hyperthermia to treatment regimens for acute and chronic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(9):1050-6.
1984: ME Trigg; R Billing; Paul M Sondel; J D Dickerman; C Erickson; Jonathan Lester Finlay; M Bozdech; R Hong; H Padilla-Nash; P Terasaki
Depletion of T cells from human bone marrow with monoclonal antibody CT-2 and complement.
Journal of biological response modifiers 1984;3(4):406-12.
1984: J A Hank; Paul M Sondel
Recognition of autologous lymphoblastoid cells by cloned human T cells: inhibition of cytotoxicity by anti-HLA antibody but not by antibody to Epstein-Barr virus induced cell surface antigen.
Human immunology 1984;9(4):211-9.
1984: Paul M Sondel; M W Ritter; D G Wilson; L M Lieberman
Use of 111In platelet scans in the detection and treatment of Kasabach-Merritt syndrome.
The Journal of pediatrics 1984;104(1):87-9.
1984: Paul M Sondel; P C Kohler; Jacquelyn A Hank; M J Bozdech; L M Lieberman; R Hong; R Albertini; R E Exten
The in vivo distribution of indium-111 labeled in vitro alloactivated syngeneic lymphocytes in a patient with relapsed acute myelomonocytic leukemia: implications for adoptive chemoimmunotherapy.
Leukemia research 1984;8(5):893-903.
1983: Paul M Sondel; ME Trigg; R Hong; Jonathan Lester Finlay; M J Bozdech
Pediatric bone marrow transplantation: current progress and future prospects.
Pediatrics 1983;72(6):818-23.
1983: Paul M Sondel
Bone marrow transplantation as immunotherapy.
Wisconsin medical journal 1983;82(10):17-9.
1983: J A Brewer; J A Hank; T Wendel; G J Schmeling; J L Blank; L W Morrissey; H I Robins; Paul M Sondel
Heated lymphocytes express HLA-DR antigens despite their inability to stimulate in MLC.
Tissue antigens 1983;22(4):246-56.
1983: Pamela Reitnauer; L R Brown; J A Hank; Paul M Sondel
Proliferative responses to a nonspecific factor produced by irradiated stimulating cells can simulate antigen-specific secondary responses in the primed lymphocyte test.
Journal of immunology (Baltimore, Md. : 1950) 1983;131(1):165-70.
1983: M E Trigg; D B Kohn; Paul M Sondel; P J Chesney
Tracheal aspirate examination for Pneumocystis carinii cysts as a guide to therapy in pneumocystis pneumonia.
The Journal of pediatrics 1983;102(6):881-3.
1983: Paul M Sondel; Jacquelyn A Hank; T Wendel; B Flynn; M J Bozdech
HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.
The Journal of clinical investigation 1983;71(6):1779-86.
1983: D J Ganick; Paul M Sondel; E F Gilbert; W Borcherding
Leukemia presenting as central nervous disease without bone marrow involvement.
Medical and pediatric oncology 1983;11(4):229-32.
1983: J A Hank; Paul M Sondel
Cell mediated lysis of lymphocytes expressing bacterial antigens.
Advances in experimental medicine and biology 1983;162():189-95.
1982: J A Hank; Paul M Sondel
Soluble bacterial antigen induces specific helper and cytotoxic responses by human lymphocytes in vitro.
Journal of immunology (Baltimore, Md. : 1950) 1982;128(6):2734-8.
1982: Paul M Sondel; E M Sparks; N R Glass; H W Sollinger; F O Belzer
Prospective renal allograft matching by pool primed lymphocyte typing. No correlation because of poor responses of prospective recipients.
Transplantation 1982;33(3):224-7.
1981: Paul M Sondel; J A Hank
Alien-driven diversity and alien-selected escape: a rationale for allogeneic cancer immunotherapy.
Transplantation proceedings 1981;13(4):1915-21.
1981: Paul M Sondel; W Borcherding; N T Shahidi; D J Ganick; J C Schultz; R Hong
Recategorizing childhood acute lymphoblastic leukemia with monoclonal antibodies to human T cells.
Blood 1981;57(6):1135-7.
1981: Paul M Sondel; M E Tripp; D J Ganick; J M Levy; N T Shahidi
Phlebotomy with iron therapy to correct the microcytic polycythemia of chronic hypoxia.
Pediatrics 1981;67(5):667-70.
1980: F H Bach; P A Paciucci; S Macphail; Paul M Sondel; B J Alter; J M Zarling
Antitumor cytotoxic T cells and non-T-cells generated by allosensitization in vitro.
Transplantation proceedings 1980;12(1):2-7.
1980: Paul M Sondel; F H Bach
The alienation of tumor immunity: alien-driven diversity and alien-selected escape.
Transplantation proceedings 1980;12(1):211-5.
1979: F H Bach; J E Gose; B J Alter; Paul M Sondel; M L Bach
Past, present, and future aspects of histocompatibility.
Transplantation proceedings 1979;11(1):1207-11.
1979: A Bernstein; M L Sopori; J E Gose; Paul M Sondel
Modulation of immune response by alloactivated suppressor T cells.
Transplantation proceedings 1979;11(1):997-1001.
1979: F H Bach; Paul M Sondel; J M Zarling
Elicitation of anti-leukemia cytotoxic responses.
Haematology and blood transfusion 1979;23():369-76.
1977: E Valentine; C Y Shih; M J Sheehy; Paul M Sondel; F H Bach
Role of non-HLA antigens in primed LD typing.
Transplantation proceedings 1977;9(1):417-9.
1977: F H Bach; O J Kuperman; H W Sollinger; J M Zarling; Paul M Sondel; B J Alter; M L Bach
Cellular immunogenetics and LD-CD collaboration.
Transplantation proceedings 1977;9(1):859-63.
1977: Paul M Sondel; F H Bach
Immunogenetic complexity of HLA-D.
Transplantation proceedings 1977;9(1):401-3.
1977: F H Bach; M L Bach; Paul M Sondel; M J Sheehy; E Jarrett-Toth; C Benike; C Kan
Assay of HLA-D disparity.
Transplantation proceedings 1977;9(1 Suppl 1):61-5.
1977: F H Bach; C Grillot-Courvalin; O J Kuperman; H W Sollinger; C Hayes; Paul M Sondel; B J Alter; M L Bach
Antigenic requirements for triggering of cytotoxic T lymphocytes.
Immunological reviews 1977;35():76-96.
1977: F H Bach; M L Bach; O J Kuperman; H W Sollinger; Paul M Sondel
Cellular recognition of major histocompatibility complex antigens.
Cold Spring Harbor symposia on quantitative biology 1977;41 Pt 2():429-41.
1977: Paul M Sondel; M W Jacobson; F H Bach
Selective activation of human suppressor cells by a nonproliferative stimulus.
European journal of immunology 1977;7(1):38-40.
1977: C Y Shih; E A Valentine; M J Sheehy; Paul M Sondel; F H Bach
Lack of restimulation by non-HLA antigens in primed lymphocyte typing.
Scandinavian journal of immunology 1977;6(5):501-5.
1977: F H Bach; E K Jarrett-Toh; C J Benike; C Y Shih; E A Valentine; Paul M Sondel; M L Bach
Primed LD typing: reagent preparation and definition of the HLA-D-region antigens.
Scandinavian journal of immunology 1977;6(5):469-75.
1976: Paul M Sondel; C O'Brien; L Porter; S F Schlossman; L Chess
Cell-mediated destruction of human leukemic cells by MHC identical lymphocytes: requirement for a proliferative trigger in vitro.
Journal of immunology (Baltimore, Md. : 1950) 1976;117(6):2197-203.
1976: Paul M Sondel; M J Sheehy; C Benike; B J Alter; F H Bach
Specific detection of HLA-D antigens using primed LD typing (PLT).
Transplantation proceedings 1976;8(3):449-53.
1976: F H Bach; E Jarrett-Toth; C J Benike; M J Sheehy; Paul M Sondel; M L Bach
Three HLA-D region antigens defined by primed LD typing.
The Journal of experimental medicine 1976;144(2):549-54.
1976: B J Alter; C Grillot-Courvalin; M L Bach; K S Zier; Paul M Sondel; F H Bach
Secondary cell-mediated lympholysis: importance of H-2 LD and SD factors.
The Journal of experimental medicine 1976;143(5):1005-14.
1976: Paul M Sondel; F H Bach
Recognitive specificity of human cytotoxic T lymphocytes. II. The non-recognition of antigens controlled outside the major histocompatibility complex.
Tissue antigens 1976;7(3):173-80.
1976: F H Bach; M L Bach; Paul M Sondel
Differential function of major histocompatibility complex antigens in T-lymphocyte activation.
Nature 1976;259(5541):273-81.
1975: Paul M Sondel; M W Jacobson; F H Bach
Pre-emption of human cell-mediated lympholysis by a suppressive mechanism activated in mixed lymphocyte cultures.
The Journal of experimental medicine 1975;142(6):1606-11.
1975: Paul M Sondel; F H Bach
Recognitive specificity of human cytotoxic T lymphocytes. I. Antigen-specific inhibition of human cell-mediated lympholysis.
The Journal of experimental medicine 1975;142(6):1339-48.
1975: Paul M Sondel; L Chess; S F Schlossman
Immunologic functions of isolated human lymphocyte subpopulations. IV. Stimulation of MLC and CML by human T cells.
Cellular immunology 1975;18(2):351-9.
1975: M J Sheehy; Paul M Sondel; M L Bach; R Wank; F H Bach
HL-A LD (lymphocyte defined) typing: a rapid assay with primed lymphocytes.
Science (New York, N.Y.) 1975;188(4195):1308-10.
1975: Paul M Sondel; L Chess; R P MacDermott; S F Schlossman
Immunologic functions of isolated human lymphocyte subpopulations. III. Specific allogeneic lympholysis mediated by human T cells alone.
Journal of immunology (Baltimore, Md. : 1950) 1975;114(3):982-7.
1973: F H Bach; K S Zier; Paul M Sondel
The nature of cells responding in mixed leukocyte cultures and cell-mediated lympholysis.
Transplantation proceedings 1973;5(4):1717-20.
1973: F H Bach; M Segall; K S Zier; Paul M Sondel; B J Alter; M L Bach
Cell mediated immunity: separation of cells involved in recognitive and destructive phases.
Science (New York, N.Y.) 1973;180(4084):403-6.
1973: Paul M Sondel; F H Bach
Antigen-specific lymphoblastoid cell lines: possible methods for establishment and potential application in systems of delayed hypersensitivity.
Birth defects original article series 1973;9(1):98-110.
1972: M B Widmer; Paul M Sondel; F H Bach
Responsiveness of germfree mice in mixed leukocyte culture. Reexamining the nature of the responding unit.
The Journal of experimental medicine 1972;136(2):398-402.
1972: F H Bach; M L Bach; Paul M Sondel; G Sundharadas
Genetic control of mixed leukocyte culture reactivity.
Transplantation reviews 1972;12():30-56.